Cann10 International Ltd.

cann10.com

Formerly Brainose Technologies

High-Tech Company

Ceased to Operate Q1/2024

TECH VERTICALS

AgriBiotech, AgriTech, Medical Cannabis

General Data

Sector	Agritech
Company Stage:	R&D
Established	2017
Number of Employees	5
Reg. Number:	abCDe

DESCRIPTION

Cann10 is one of the leading medical cannabis companies in Israel and the world.
Their extensive network of educational and research resources includes major medical institutions, universities, and agricultural centers, experience, expertise, and know-how of global trade in Israel, Brazil, Australia, and Europe.

Cann10 bolsters the medical cannabis industry through 4 main business verticals from seed to sale: Cann10XL – Cannabis Innovation Hub,“Cannareet” Medical Cannabis products, Cann10 International - A global network of
partners who enable global trade, cannabis cultivation, and extraction facilities, and Cann10 Education - Academic courses and high-level
professional conferences.

TECHNOLOGY

Despite enormous advances in brain research, brain and central nervous system (CNS) disorders remain the world's leading cause of disability, and account for more hospitalizations and prolonged care than most other diseases combined. Although many advanced and effective approaches to brain delivery of drugs have emerged in recent years, delivery of drugs to the central nervous system (CNS) remains a challenge in the development of effective agents for CNS targets, mainly due to the impenetrable nature of the blood brain barrier (BBB). Various approaches such as BBB disruption, invasive intrathecally administration, implantable infusion systems, targeted delivery and drug delivery vehicles has yet been shown to be safe and effective for delivering chronic treatments to the brain. An increasing number of studies on both animals and human subjects have suggested that intranasal drug delivery could be used to deliver therapeutics into the CNS, bypassing the BBB.

TARGET MARKETS

Cann10 collaborates with first in line academia and industry professionals to design and develop the next generation Cannabinoids based therapeutics nasal delivery products. Cann10 collaborates with key opinion leaders in CNS disease research, drug development and clinical research. Their technology enables drug molecules of vast chemical and pharmaceutical characteristics, to reach the brain faster and more efficient with higher safety and improved patient experience. Cann10 collaborates with other Cannabinoid based therapeutics developers for co-development or licensing of its technology to meet specific therapeutic needs.

	BUSINESS MODEL
	B2C

REMARKS

Date	Remark
	The Company partnered with SipNose LTD. towards co-development of cannabis-derived therapeutics with innovative pharmaceutical formulations and SipNose’s innovative nose-to-brain delivery platform.

CONTACT INFO

Expand / Collapse All

Main Address: Rosh Haayin, Israel

Address	22 Hamelacha St.
City	Rosh Haayin
Country	Israel
Zip	4809162

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Yossi Bornstein	Founder	WaterSheer (Business Development Consultant)

	Non-Equity Assistance

Expand / Collapse All

Date

Stage

Remarks

Non-Equity Assistance

Nov. 01, 2017

Seed

Contributor	Type	Amount	Remarks
abC Defghij	High-Tech Company	abCDe

Non-Equity Assistance

Nov. 01, 2017

Seed

Contributor	Type	Amount	Remarks
abC Defghij	Corporate Accelerator	abCDe

Last Updated:	abCDe
IVC Number:	abCDe